P1340 Gut microbiota changes are associated with type of advanced therapy in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome study
Robert D. Little(Hospital Universitario Fundación Jiménez Díaz), Georgina L. Hold(University of Aberdeen), Thisun Jayawardana(Sutherland Hospital), Peter R. Gibson(Monash University), Rupert W. Leong(The University of Sydney), Sabrina Koentgen(UNSW Sydney), Daniel A. Lemberg(UNSW Sydney), Simon Ghaly(UNSW Sydney), Nan Wu(Chongqing University), Susan J. Connor(Liverpool Hospital), Steven T. Leach(UNSW Sydney), Shoma Dutt(The University of Sydney), Ambrose Chung‐Wai Ho(UNSW Sydney), Alex Boussioutas(The Royal Melbourne Hospital), Miles Sparrow(Alfred Health), Fan Zhang(Sun Yat-sen University), Mark G. Ward(The Alfred Hospital), Nicholas J. Talley(University of Newcastle Australia), Crispin Corte(Royal Prince Alfred Hospital), P Tavakoli(University of British Columbia), Sudarshan Paramsothy(University of Chicago), A Chung(UNSW Sydney), Stephen Read(UNSW Sydney)
Cited by 0
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
|Gastroenterology|2013|938
Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of Living Patients With Alzheimer Disease
|American Journal of Geriatric Psychiatry|2002|771
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
|Gastroenterology|2013|725
Immune Activation in Patients With Irritable Bowel Syndrome
|Gastroenterology|2007|662